MedTrace Logo

DynamX Bioadaptor Hong Kong Registry

NCT04483791 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-17

Study results available
· View outcomes & findings →

Summary

Prospective, non-randomized, multicenter registry

Conditions

Interventions

COMBINATION_PRODUCT

DynamX Novolimus Eluting Coronary Bioadaptor System

up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System

Sponsors & Collaborators

  • Elixir Medical Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483791 on ClinicalTrials.gov